AUSTIN COMBS: Open Payments
NPI 1215660683 · NOBLESVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,356 in 70 payments from 22 companies in 2025. Trend: 2023 $32 · 2024 $614 · 2025 $1,356
Food & beverage: $1,356
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $234 |
| Regeneron Healthcare Solutions, Inc. | 11 | $197 |
| GENZYME CORPORATION | 12 | $187 |
| GlaxoSmithKline, LLC. | 9 | $176 |
| Lilly USA, LLC | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Viatris Specialty LLC | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Philips North America LLC | 2 | $43 |
| Amgen Inc. | 2 | $38 |
Products named: DUPIXENT, NUCALA, FASENRA, TEZSPIRE, ZEPBOUND, GLASSIA, YUPELRI, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
